Join to access to all OVN content. Join for Free
The Power of Commercial Leadership in Oncology

The Power of Commercial Leadership in Oncology


Share This Article


Summary

Discover how commercial leadership, collaboration, and clear communication shape success in oncology—and why patients depend on it.

 

What does it mean to be the true “voice of commercial” in oncology, and why does it matter more than ever?

 

In this episode of Oncology Voice Network Podcast, join Dr. Kirk Shepard as he welcomes Daniel Switzer, Head of U.S. Oncology at Daiichi Sankyo, for a revealing look inside the commercial engine that drives cancer innovation from the lab all the way to the patient. With two decades of leading launches, transformations, and cross-functional teams, Daniel Switzer shares his most pivotal moments, from high-stakes encounters with patients to standing ovations at ASCO Congress.

 

Discover why commercial is about so much more than sales, how ethical responsibility and clear alignment can truly change outcomes, and what happens when teams get it wrong. Daniel Switzer discusses breaking down silos, building bridges with R&D, and the necessity of early, unified collaboration in launching life-changing therapies. Plus, hear why the Oncology Voice Network and industry-wide learning are the next frontiers in elevating patient care.

 

Whether you're in pharma, research, or just passionate about innovation, this episode will reframe what commercial leadership means in today’s oncology world.

 

Tune in now and get inspired to bridge the gaps that matter most.

 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
External control arms in oncology: current use and future directions
OVN Avatar P.S. Mishra-Kalyani, L. Amiri Kordestani, D.R. Rivera, H. Singh, A. Ibrahim, R.A. DeClaro, Y. Shen, S. Tang, R. Sridhara, P.G. Kluetz, J. Concato, R. Pazdur, J.A. Beaver

External control arms in oncology: current use and future directions

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN